3.36
0.05 (1.51%)
| Previous Close | 3.31 |
| Open | 3.29 |
| Volume | 2,018,832 |
| Avg. Volume (3M) | 1,902,746 |
| Market Cap | 314,176,000 |
| Price / Sales | 0.570 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Profit Margin | -15.96% |
| Operating Margin (TTM) | -9.49% |
| Diluted EPS (TTM) | -0.700 |
| Quarterly Revenue Growth (YOY) | 10.30% |
| Total Debt/Equity (MRQ) | 2,020.06% |
| Current Ratio (MRQ) | 1.79 |
| Operating Cash Flow (TTM) | -15.64 M |
| Levered Free Cash Flow (TTM) | 5.58 M |
| Return on Assets (TTM) | -17.66% |
| Return on Equity (TTM) | -277.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Mixed | Mixed |
| Medical Care Facilities (Global) | Mixed | Mixed | |
| Stock | The Oncology Institute, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Investment Style | Small Value |
| % Held by Insiders | 9.22% |
| % Held by Institutions | 34.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Josh Arnold Investment Consultant, Llc | 30 Jun 2025 | 2,446,550 |
| Tiff Advisory Services, Llc | 30 Sep 2025 | 856,628 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (BTIG, 108.33%) | Buy |
| Median | 6.00 (78.57%) | |
| Low | 5.00 (Needham, 48.81%) | Buy |
| Average | 6.00 (78.57%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 25 Nov 2025 | 5.00 (48.81%) | Buy | 3.16 |
| BTIG | 21 Oct 2025 | 7.00 (108.33%) | Buy | 4.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Dec 2025 | Announcement | The Oncology Institute Announces Resignation of Board Member Gabe Ling |
| 13 Nov 2025 | Announcement | The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance |
| 13 Nov 2025 | Announcement | Ascertain and The Oncology Institute Co-Develop ‘Touchless’ AI Automation for Oncology Administration |
| 22 Oct 2025 | Announcement | The Oncology Institute Announces Third Quarter 2025 Earnings Release Date and Conference Call |
| 01 Oct 2025 | Announcement | The Oncology Institute to Participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference |
| 29 Sep 2025 | Announcement | The Oncology Institute Partners with Protocol Behavioral Health to Integrate Mental Health Services into Cancer Care |
| 22 Sep 2025 | Announcement | The Oncology Institute Achieves $1.1 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 2 through its California Professional Corporation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |